Zhijian James Chen

Zhijian James Chen
Nationality Chinese
Institutions
Alma mater

Zhijian James Chen (陈志坚) is a Chinese American biochemist and Professor in the Department of Molecular Biology at University of Texas Southwestern Medical Center. He is best known for using classical biochemistry to discover new pathways and mechanisms in innate immunity and cell signaling. His scientific contributions include the discovery of a proteasome-independent role of ubiquitin in protein kinase activation, the discovery of MAVS (Mitochondrial Anti-Viral Signaling protein) and the role of mitochondria in antiviral innate immune responses, and the more recent discoveries of the cytosolic DNA sensor, Cyclic GMP-AMP synthase (cGAS; cGAMP synthase), and a new second messenger, Cyclic guanosine monophosphate–adenosine monophosphate (cyclic GMP-AMP, cGAMP), which play key roles in immune defense as well as autoimmune diseases.[1] He has won numerous distinctions for his scientific contributions including the Norman Hackerman Award in Chemical Research, The Edith and Peter O’Donnell Award in Science, and the National Academy of Sciences Award in Molecular Biology. James currently holds the George L. MacGregor Distinguished Chair in Biomedical Science and is an Investigator of the Howard Hughes Medical Institute.[2] He is a member of the National Academy of Sciences.[3]

Early life and education

Chen was born in Nantou (南斗村), a small village in Anxi County, Quanzhou, Fujian. When he was young, his father was sent to Nanping for work, leaving his mother to raise him and his two brothers alone while she also worked as a primary school teacher. He graduated from Anxi No. 1 High School in 1981.[4] He attended Fujian Normal University and received an undergraduate degree in biology in 1985, before he won an overseas scholarship by getting first place in a biochemistry exam. Chen used the scholarship to attend the State University of New York at Buffalo, where he got his Ph.D. in biochemistry in 1991.[2][5] During his graduate education, Chen became interested in the biochemical pathway of the protein ubiquitin at a time when less than a dozen laboratories were researching the protein's function in the human body.[6] After graduating, Chen did a year of post-doctoral work with the Salk Institute for Biological Studies.[7]

Career

Following his post-doctoral work, Chen began working as a research scientist at Baxter Healthcare in Irvine, California. He then spent three years working as a senior scientist at biotech firm ProScript in Cambridge, Massachusetts, where he developed assays that helped to identify and improve the cancer treatment Velcade. His time at ProScript allowed Chen to work in molecular biology and drug development and it was while working there that Chen started researching ubiquitin.[5][7] Working with Tom Maniatis of Harvard University in 1996, Chen found that the enzyme kinase had to be "activated" by ubiquitin in order for the NF-κB signalling process to function properly. He decided pursuing his research into ubiquitin would be more suited for work in academia and left ProScript in 1997 to start a lab at the University of Texas Southwestern Medical Center in Dallas.[6]

Research

Chen's research initially focused on the role of ubiquitin in signaling pathways for the NF-κB protein complex, specifically as it pertains to immune response. At his lab in UT-Southwestern, Chen's group was able to show that ubiquitin marked proteins, mark that could be recognized by other proteins to create a "cascade" of signals.[6] His research received grant funding from the Burroughs Wellcome Fund in 2002.[8] Chen used the additional funding to expand his research into how NF-κB initiated immune responses to RNA viruses such as influenza and hepatitis C. This new line of research led to several discoveries, such as MAVS, cGAS and cGAMP, which contribute to understanding innate immune sensing and signaling of cytosolic nucleic acids.

References

This article is issued from Wikipedia - version of the 11/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.